Description

Halozyme Therapeutics: European Market Expansion to Capture The Oncology Treatment Market! 

Halozyme Therapeutics delivered robust financial and operational performance in 2024, evidenced by total revenue surpassing the $1 billion mark for the first time, reflecting a 22% increase over the prior year. This achievement was primarily driven by strong royalty revenue growth, which rose 27% to $571 million, along with significant milestones in their collaborative agreements. The company’s high-margin royalty revenue was supported by the commercial success of subcutaneous formulations of DARZALEX, Phesgo, and the new introduction of VYVGART Hytrulo for generalized myasthenia gravis (gMG).

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!